Cargando…

Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life

Despite in vitro activity of interferon-β (IFN-β) against SARS-CoV-2 infection, its clinical efficacy remains controversial. We evaluated the impact of IFN-β treatment in a cohort of 3590 patients hospitalized with COVID-19 during March–April 2020. The primary endpoint was a composed variable of adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Casado, José L., Vizcarra, Pilar, Del Rey, José M., Soriano, María Cruz, Rodriguez-Dominguez, Mario, Manzano, Luis, Acero, Julio, Palomar-Fernandez, Carmen, Vallejo, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739717/
https://www.ncbi.nlm.nih.gov/pubmed/36498527
http://dx.doi.org/10.3390/jcm11236952
_version_ 1784847877645795328
author Casado, José L.
Vizcarra, Pilar
Del Rey, José M.
Soriano, María Cruz
Rodriguez-Dominguez, Mario
Manzano, Luis
Acero, Julio
Palomar-Fernandez, Carmen
Vallejo, Alejandro
author_facet Casado, José L.
Vizcarra, Pilar
Del Rey, José M.
Soriano, María Cruz
Rodriguez-Dominguez, Mario
Manzano, Luis
Acero, Julio
Palomar-Fernandez, Carmen
Vallejo, Alejandro
author_sort Casado, José L.
collection PubMed
description Despite in vitro activity of interferon-β (IFN-β) against SARS-CoV-2 infection, its clinical efficacy remains controversial. We evaluated the impact of IFN-β treatment in a cohort of 3590 patients hospitalized with COVID-19 during March–April 2020. The primary endpoint was a composed variable of admission to intensive care unit (ICU)/death. Overall, 153 patients (4%) received IFN-β. They were significantly more severely ill, with a worse clinical and analytical situation, explaining a higher ICU admission (30% vs. 17%; p < 0.01), and a shorter time to the composed variable. In a Cox regression analysis, older age, lymphopenia, renal failure, or increased neutrophil-to-lymphocyte ratio were associated with a greater hazard ratio (HR) of admission at ICU/death. Notably, the HR of IFN-β for the outcome variable was no longer significant after adjustment (HR, 1.03; 95% CI, 0.82–1.30), and different sensitivity analysis (early IFN use, ICU admission) showed no changes in the estimates. A propensity score matching analysis showed no association of IFN-β therapy and outcome. In conclusion, in this large cohort of hospitalized COVID-19 patients, IFN-β was used mainly in patients with advanced disease, reflecting an important bias of selection. After adjusting by severity, IFN-β was not associated with a higher rate of ICU admission or mortality.
format Online
Article
Text
id pubmed-9739717
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97397172022-12-11 Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life Casado, José L. Vizcarra, Pilar Del Rey, José M. Soriano, María Cruz Rodriguez-Dominguez, Mario Manzano, Luis Acero, Julio Palomar-Fernandez, Carmen Vallejo, Alejandro J Clin Med Article Despite in vitro activity of interferon-β (IFN-β) against SARS-CoV-2 infection, its clinical efficacy remains controversial. We evaluated the impact of IFN-β treatment in a cohort of 3590 patients hospitalized with COVID-19 during March–April 2020. The primary endpoint was a composed variable of admission to intensive care unit (ICU)/death. Overall, 153 patients (4%) received IFN-β. They were significantly more severely ill, with a worse clinical and analytical situation, explaining a higher ICU admission (30% vs. 17%; p < 0.01), and a shorter time to the composed variable. In a Cox regression analysis, older age, lymphopenia, renal failure, or increased neutrophil-to-lymphocyte ratio were associated with a greater hazard ratio (HR) of admission at ICU/death. Notably, the HR of IFN-β for the outcome variable was no longer significant after adjustment (HR, 1.03; 95% CI, 0.82–1.30), and different sensitivity analysis (early IFN use, ICU admission) showed no changes in the estimates. A propensity score matching analysis showed no association of IFN-β therapy and outcome. In conclusion, in this large cohort of hospitalized COVID-19 patients, IFN-β was used mainly in patients with advanced disease, reflecting an important bias of selection. After adjusting by severity, IFN-β was not associated with a higher rate of ICU admission or mortality. MDPI 2022-11-25 /pmc/articles/PMC9739717/ /pubmed/36498527 http://dx.doi.org/10.3390/jcm11236952 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Casado, José L.
Vizcarra, Pilar
Del Rey, José M.
Soriano, María Cruz
Rodriguez-Dominguez, Mario
Manzano, Luis
Acero, Julio
Palomar-Fernandez, Carmen
Vallejo, Alejandro
Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
title Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
title_full Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
title_fullStr Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
title_full_unstemmed Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
title_short Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
title_sort lost in translation: evaluation of subcutaneous interferon-β treatment for sars-cov-2 infection in real life
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739717/
https://www.ncbi.nlm.nih.gov/pubmed/36498527
http://dx.doi.org/10.3390/jcm11236952
work_keys_str_mv AT casadojosel lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT vizcarrapilar lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT delreyjosem lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT sorianomariacruz lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT rodriguezdominguezmario lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT manzanoluis lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT acerojulio lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT palomarfernandezcarmen lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT vallejoalejandro lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife
AT lostintranslationevaluationofsubcutaneousinterferonbtreatmentforsarscov2infectioninreallife